13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • XL184-312

    Acronym: 

    COSMIC

    ACTRN/NCT /ethics: 

    NCT03755791

    Scientific title: 

    Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

    Summary of trial and patient characteristics

    Cancer Type Liver
    Trial Type Treatment
    Phase Phase III Tumour Stream Hepatocellular Carcinoma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2018-12-10
    Molecular Target Anticipated End Date 2021-12-01
    Cancer Type Liver
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Hepatocellular Carcinoma
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2018-12-10
    Anticipated End Date 2021-12-01

    Trial Summary

    This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

    Lay Summary

    Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

    Sponsor / Cooperative group

    Exelixis

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 9 8292 2240 Recruiting